Diabetic Neuropathy Market Analysis 2026

Market Dynamics of the Diabetic Neuropathy Market

Key Drivers of the Diabetic Neuropathy Market

• Growing awareness among people and increasing dependence on diabetes control measures to boost market growth

With chronic diabetes becoming more commonplace worldwide, there is a sizable patient base. Thus, whether or not someone they know has experienced it, people all over the world have gradually become more aware of the same. In addition, a lot of efforts have been made to raise awareness of these complications associated with diabetes, which is driving demand for care and treatment services. The increasing public awareness of healthcare facilities and preventive treatments, which are expanding to accommodate more services, is also contributing to the development of the market. WHO and IDF are working together to prevent & control diabetes and ensure good quality of life for people worldwide.
•    For instance, the WHO Diabetes Program is aimed at preventing type 2 diabetes, reducing complications, and improving the quality of life for people with diabetes.
(Source:https://www.who.int/initiatives/the-who-global-diabetes-compact)

• Rapidly increasing chronic diabetic patients globally significantly drive the market

One of the most common illnesses with serious negative effects on human health is diabetes. These chronic lifestyle diseases have a wide geographic distribution and have been linked to people from all socioeconomic backgrounds. During the projection period, the global demand for diabetic neuropathy would grow at a slower rate due to the rising prevalence of diabetes. In addition, several conditions including obesity, heart disease, diabetic neuropathy, and other problems with sugar are believed to be contributing to the market's growth. Growing urbanization, which encourages sedentary lifestyles like consuming carbohydrates and engaging in little physical activity, has an impact on the market's growth as well. 
•    For instance, Diabetes currently has a global prevalence rate of 6.1%, ranking it among the top ten leading causes of death and disability. 
(Source:https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death)

Restraints of the Diabetic Neuropathy Market

• Highly-priced medications and alternative treatments hinder market growth.

Some of the obstacles to market expansion include the growing cost of diabetic neuropathy medications, the growing availability of alternative medications, and other factors. The availability of alternative therapies like physiotherapy and radiotherapy, which are regarded as more comfortable and may offer patients satisfactory clinical results, is one factor limiting the market's potential. Given the continued global increase in the prevalence of both diabetes and related neuropathy, the degree of regional expansion in the treatment of diabetic neuropathy can be regarded as moderate. Tight regulations, product recalls, delays in Food and Drug Administration clearances, and other issues of a similar nature could also impede the growth of this market.
•    For instance, duloxetine can range from $9.00 to $54.31. Thus, the high cost of drugs used for the treatment of diabetic peripheral neuropathy may hinder the growth of the market during the forecast period.
(Source:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3150163/)

How Did COVID-19 Impact the Diabetic Neuropathy Market

The COVID-19 pandemic significantly impacted the diabetes drug market in various ways. Firstly, people with diabetes were identified as a high-risk group for severe COVID-19 complications, leading to increased demand for diabetes medication as patients sought to better manage their conditions to reduce the risk. However, disruptions in healthcare services, including limited access to clinics and hospitals, impacted the diagnosis and management of diabetes for some patients. This could have led to fluctuations in demand for diabetes drugs. The economic repercussions of the patient's ability to afford medications, potentially lead to changes in purchasing patterns or adherence to treatment regimens. In terms of research and development, the focus on COVID-19-related treatments and vaccines may have diverted resources and attention away from diabetes drug development, impacting innovation in the field. Some studies show that the use of metformin, an oral antihyperglycemic, is associated with reduced COVID-19 severity in individuals with diabetes compared to other antihyperglycemic medications.
•    For instance, a new study found that taking metformin, a commonly used diabetes drug, after testing positive for Covid-19 may cut the risk of developing long Covid-19 by 40%. Metformin is a medication that helps control blood sugar levels in people with type-2 diabetes and is widely used in India to treat the disease.
(Source:https://www.business-standard.com/health/cheap-diabetes-drug-could-cut-risk-of-developing-long-coronavirus-study-123060900301_1.html)

Opportunities of the Diabetic Neuropathy Market

• Growing research and development activities by key players to fuel the global diabetic neuropathy market.

The number of elderly people and their consumption of carbohydrates is rising, which is contributing to an increase in the incidence of diabetes. With the growing number of people with diabetes worldwide, there is an increasing need for treatments for diabetic neuropathy. The market is expanding thanks in part to increased government spending on improving healthcare. stem cell therapy and targeted drug delivery systems are being explored, offering hope for more effective management and potential reversal of neuropathy symptoms. The sector for diabetic neuropathy is anticipated to increase shortly due to the quick advances in science and the rising investments made by the major industry participants. Diabetic neuropathy’s therapeutic arm is witnessing a sizable expenditure to launch new medications.
•    For instance, in December 2023, Vertex Pharmaceuticals Inc. announced affirmative results from the Phase II dose-ranging study of selective Nav1.8 inhibitor VX-548 in those contracting painful diabetic peripheral neuropathy.
(Source:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3150163/)

•    For instance, in July 2023, Aspirus Lifesciences developed a drug for diabetic neuropathy. It filed a patent for treatment which comprises a fixed dose combination of two drugs. R&D of such drugs is augmenting diabetic neuropathy market value.
(Source:https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/asprius-lifesciences-develops-drug-for-diabetic-neuropathy-files-patent/articleshow/102180158.cms?from=mdr)

The global market for diabetic neuropathy is being driven, among other things, by rising market developments and rising diabetes cases. The need for diabetic neuropathy treatments offered by hospital pharmacies has been rising steadily due to the increased prevalence of diabetes worldwide, which has fueled the segment's expansion. The sector for diabetic neuropathy is anticipated to increase shortly due to the quick advances in science and the rising investments made by the major industry participants. Diabetic neuropathy’s therapeutic arm is witnessing a sizable expenditure to launch new medications.

Frequently Asked Questions